<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932737</url>
  </required_header>
  <id_info>
    <org_study_id>202.839</org_study_id>
    <secondary_id>U09-3181-01</secondary_id>
    <nct_id>NCT00932737</nct_id>
  </id_info>
  <brief_title>(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Parallel-group Pilot Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used on Demand for the Treatment of Self-reported Functional Abdominal Pain Associated With Cramping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB)
      20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment
      of intensity of abdominal pain associated with cramping (APC) in the treatment of two
      episodes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in intensity of APC based on the 0 to 10 point scale.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) calculated from the responses to the 0 to 10 point scale.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response based the 0 to 10 point scale as defined by: a response of no pain at any interval.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response based the 7-point Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response based the 4-point Verbal Rating Scale (VRS) of the patient's global assessment of efficacy</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to relief</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of tablets of study medication taken</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of tolerability.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination: changes in pulse rate, diastolic and systolic blood pressure,</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body temperature and respiratory rate.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>HBB 20mg 1-5 tablets per episode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive 1-5 tablets containing 20mg HBB per APC episode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-5 tablets per episode</description>
    <arm_group_label>HBB 20mg 1-5 tablets per episode</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-5 tablets per episode</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBB 20 mg</intervention_name>
    <description>Active drug, one to five tablets per episode</description>
    <arm_group_label>HBB 20mg 1-5 tablets per episode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        History of recurrent abdominal pain with cramping (APC) for at least three months.

        Recorded at least two episodes of APC of at least &quot;moderate&quot; intensity (i.e., 5 or above on
        a 0-10 point scale) lasting one hour in the eDiary during the run-in period.

        Exclusion Criteria:

        Experiencing daily episode of APC during Run-in period Active gastrointestinal disease
        during the past 12 months including malignancy, inflammatory bowel disease, celiac disease
        or complete or partial bowel obstruction and who have undergone major gastrointestinal
        surgery with the past 12 months (patients with history of appendectomy, cholecystectomy,
        bilateral tubal ligation and c-section within past 12 months are allowed in the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>202.839.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywwod</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.839.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

